Navigation Links
The search for an early biomarker to fight atherosclerosis
Date:5/13/2013

Montral, May 14, 2013 It's on Saturday that the Journal of the American Heart Association published the conclusive results from a study directed by Dr. ric Thorin of the Montreal Heart Institute (MHI), which suggests for the first time that a blood protein contributes to the early development of atherosclerosis.

Dr. Thorin, his team and his collaborators discovered that the blood levels of angiopoietin-like protein 2 (angptl2) are six times higher in subjects with coronary heart disease than in healthy subjects of the same age. Their basic research study also revealed that angptl2, which is undetectable in young mice, increases with age in healthy subjects and increases prematurely in subjects who have high cholesterol and pre-atherosclerotic lesions. Entitled "Angiopoietin-like 2 promotes atherogenesis in mice," this study was conducted using an animal model consisting of three to twelve-month-old mice.

These results represent a major advance in the prevention and treatment of atherosclerosis. "Although much work remains to be done to broaden our knowledge of this protein's mechanisms of action, angiopoietin-like protein 2 may represent an early biomarker not only to prevent vascular damage but also to predict atherosclerotic disease," explained Dr. Thorin.

For 15 years, Dr. Thorin, a researcher at the MHI Research Centre and full professor at Universit de Montral, has been interested in the evolution of artery function during the aging process and in the underlying mechanisms of atherosclerosis. More specifically over the past five years, he has looked at the role of this particular protein. Thanks to his work, we now know that angptl2 causes a high degree of vascular inflammation. Blood levels of this protein increase in patients with cardiovascular disease as well as in people with complications related to diabetes, obesity and cancer in which the small blood vessels are damaged, as all of these diseases are associated with chronic inflammation.

According to Dr. Anil Nigam, a cardiologist and specialist in cardiovascular disease prevention at the MHI and co-author of the study, "Prevention is the ideal solution to delay the onset of atherosclerosis, and an early blood marker such as angptl2if future clinical studies confirm this findingwill serve as an important tool to identify at-risk subjects who do not present with any symptoms of atherosclerotic disease."


'/>"/>

Contact: Marie-Josée Nantel
marie-josee.nantel@icm-mhi.org
514-376-3330
Montreal Heart Institute
Source:Eurekalert

Related medicine news :

1. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
2. Most Michigan parents, grandparents prefer research hospitals for pediatric care
3. Leap in leukemia treatment reported by Dartmouth researchers
4. Researchers discover master regulator that drives majority of lymphoma
5. Global Cell Culture Market - New Market Research Report Published by Transparency Market Research
6. Researchers develop smart phone app to help weight loss
7. Food Allergy Research & Education (FARE) Takes Action to Address Growing Problem of Food Allergy Bullying
8. POC Abused Drugs & Lipid Testing Market Analysis For US, Germany & Spain in New Research Reports at RnRMarketResearch.com
9. Global Reinsurance Carriers Industry Market Research Report from IBISWorld Has Been Updated
10. Bix of Sanders-Brown receives NIH funding for stroke research
11. Mount Sinai Researchers Identify Gene Mutations in Congenital Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... Myers Jackson is well known for auctioning homes that people move and ... the planet. The luxury home market is alive and well and there are mansions ... of “11 Spyglass Hill Auction will enlighten you on the dynamics of how to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a trusted ... ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time visibility ... to the cloud to the edge. Through the new partnership, customers get the ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... and nonprofit hospitals and health systems in the nation and help their organizations ... led professional organizations and been instrumental in developing successful hospital and health system ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a leading ... that its iClinic V12.2 solution has achieved approval from National Center for Quality ... 2017 standards which emphasize team-based care with a significant focus on the care ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)...   Provista , a proven leader in the supply ... announced Jim Cunniff as the company,s new president ... experience to Provista, including most recently serving as the president ... . He assumed his new role with Provista on ... for Provista," says Jody Hatcher , president, Sourcing and ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology: